title: [The efficacy and limitation of hepatic arterial infusion chemotherapy for colorectal liver metastases].
abstract: We investigated the efficacy and limitation of hepatic arterial infusion (HAI) chemotherapy for colorectal liver metastases. In terms of prophylactic HAI following curative resection of liver, the 5-year disease-free survival of HAI group (12 g of 5-FU administered in 6 weeks) was 66.7%, whereas that of randomly selected control group was 20.0%. The difference was statistically significant (p = 0.045). Recurrent disease was confirmed in three cases of HAI group (one in liver) and in 8 patients of the control group (6 in liver). However, the overall survival was not significantly different between the groups. Thus, the short-term HAI of 5-FU is effective in decreasing the recurrence of disease. As for the treatment of unresectable liver metastases, some patients received HAI of 5-FU (1,000-1,500 mg/w) showed prolonged survival with partial remission of the disease. However, the 1-, 2-, and 3-year cumulative survival of HAI group (n = 27) was 69.3, 34.1 and 11.4%, respectively, against 61.3, 22.6 and 9.4%, respectively, in the transarterial embolization (TAE) group (n = 31). Therefore it is important to estimate the effect in the early phase of HAI, and aggressively continue the treatment in selected patients for whom it is suitable.
authors.affiliation: Dept. of Surgery, Kansai Rosai Hospital.
authors.forename: T
authors.initials: T
authors.lastname: Tono
authors.forename: H
authors.initials: H
authors.lastname: Ohzato
authors.forename: Y
authors.initials: Y
authors.lastname: Hasuike
authors.forename: H
authors.initials: H
authors.lastname: Watanabe
authors.forename: S
authors.initials: S
authors.lastname: Hayashi
authors.forename: M
authors.initials: M
authors.lastname: Fukunaga
authors.forename: T
authors.initials: T
authors.lastname: Aihara
authors.forename: K
authors.initials: K
authors.lastname: Kan
authors.forename: H
authors.initials: H
authors.lastname: Imamoto
authors.forename: K
authors.initials: K
authors.lastname: Yamazaki
authors.forename: N
authors.initials: N
authors.lastname: Kikkawa
authors.forename: Y
authors.initials: Y
authors.lastname: Takatsuka
mesh_terms: D000284:Administration, Oral; D016461:Chemoembolization, Therapeutic; D015179:Colorectal Neoplasms / Q000473:pathology*; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005472:Fluorouracil / Q000008:administration & dosage; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D007459:Iodized Oil / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000401:mortality / Q000556:secondary* / Q000628:therapy*; D015996:Survival Rate
chemical_list: D007459:Iodized Oil; D004317:Doxorubicin; D005472:Fluorouracil